Mirus Bio Bio-Expo Live 2024: Upstream Bioprocessing

Is your current AAV process holding you back? The short- and long-term impacts of process optimization on your gene therapy pipeline.

High yield, high quality, and high-efficiency adeno-associated virus (AAV) production is essential for advancing the field of gene therapy. Producing enough viral particles in a cost-effective manner to treat medium-high dose indications, and moderate-large prevalence diseases poses significant challenges.

To meet demand, manufacturers are often forced to scale out and scale-up, driving investment in facilities, equipment, and personnel. Upstream process optimization offers a key solution to increase overall yields and alleviate capacity constraints while removing economic barriers as processes move from the clinic to commercialization.

In this webinar, we introduce a proprietary economic model which quantitates the impact of upstream process optimization with varying transfection technologies using real world case studies. Fold improvements in AAV titer and percent full capsids as a result of different transfection technologies are evaluated with batch cost and cost-per dose comparisons.

Considerations for making changes to processes supporting early clinical AAV assets are evaluated and discussed from economic as well as practical viewpoints. Legacy versus modern process performance are compared on a batch cost and cost-per-dose basis. Long range economic modelling then demonstrates the impact of decisions made during process development and the payoff many years later for commercial manufacturing.

Finally, witness simulations in real-time with a new AAV manufacturing cost calculator. Viewers can sign-up for custom simulations comparing process specific outputs such as titer and percent full capsids.